{
    "nct_id": "NCT04469075",
    "official_title": "The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields",
    "inclusion_criteria": "* Age â‰¥18 years\n* Diagnosis of newly diagnosed or recurrent GBM with plan to initiate treatment with TTFields with or without systemic therapy, confirmed by the enrolling institution\n* Able to self-administer topical interventions or has available another person who can apply the topical agents\n* Treatment with TTF should be initiated within 7 days of planned initiation on this trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known history of allergy to any ingredient of the study agents\n* Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of the investigator, will affect the grading of skin adverse events, confirmed by enrolling institution.\n* Use of concurrent topical therapy to the scalp for another dermatologic condition\n* Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment\n* Use of greater than 4 mg dexamethasone a day within 14 days of enrollment\n* Malignant glioma\n* Pregnant Women",
    "miscellaneous_criteria": ""
}